MGC45491 Blocking Peptide
- Known as:
- MGC45491 Blocking Peptide
- Catalog number:
- 33r-1796
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Fitzgerald industries international
- Gene target:
- MGC45491 Blocking Peptide
Related genes to: MGC45491 Blocking Peptide
- Gene:
- C6orf223 NIH gene
- Name:
- chromosome 6 open reading frame 223
- Previous symbol:
- -
- Synonyms:
- MGC45491
- Chromosome:
- 6p21.1
- Locus Type:
- gene with protein product
- Date approved:
- 2007-12-19
- Date modifiied:
- 2016-09-30
Related products to: MGC45491 Blocking Peptide
Related articles to: MGC45491 Blocking Peptide
- Tissue-derived extracellular vesicles (Ti-EVs) play a crucial role in tumour progression, but their value as differential diagnostic markers for various renal cell carcinoma (RCC) subtypes remains uncertain. Through analysis of paired tumour and normal tissues, along with their corresponding Ti-EVs, we identified NEAT1 and MMP15 as markers for papillary RCC (pRCC); DSG2 and AC026888.1 for chromophobe RCC (chRCC); NDUFA4L2, SERPINA1, VEGFA, EGLN3, CPE and C6orf223 for low-grade clear cell RCC (low-grade ccRCC); and NDUFA4L2, APOC1, TGFBI and LINC00887 for high-grade ccRCC (high-grade ccRCC). In an external validation cohort, an area under the curve (AUC) of 0.922 for low-grade ccRCC detection and 0.874 for high-grade ccRCC detection was achieved, respectively, using urinary EVs. Furthermore, integrating single-cell sequencing data revealed that SERPINA1 and VEGFA in low-grade ccRCC, and APOC1 and TGFBI in high-grade ccRCC, were derived from tumour-associated macrophages, whereas NDUFA4L2 originated from cancer cells in both low- and high-grade ccRCC. - Source: PubMed
Wu XinruiZhou JialeJiang ChenChen WenjinPeng ZehongWu TianyangGe YangDu XinxingHu CongWu XiaorongHuang JiweiZhang JinCui XingangXue WeiChen YonghuiDong Liang - Colorectal cancer (CRC) is a leading cause of cancer-related mortality, with high-risk cases showing increased aggressiveness and poor prognosis. Recent studies suggest that long noncoding RNAs (lncRNAs) such as C6orf223 may play crucial roles in CRC progression. This study investigated the expression and regulatory role of C6orf223 in high-risk versus low-risk CRC patients, focusing on its potential as a biomarker for diagnosis and prognosis. We conducted differential expression analysis using RNA-seq data to identify key genes in high-risk CRC, followed by correlation and pathway enrichment analyses to understand C6orf223. Kaplan-Meier survival analysis and receiver operating characteristic (ROC) curves assessed the prognostic and diagnostic potential of C6orf223. RNA methylation and mutation patterns were analyzed to explore post-transcriptional regulation and genetic alterations in high-risk CRC. C6orf223 was significantly upregulated in high-risk CRC. High C6orf223 expression was associated with poor overall survival, and a biomarker panel that includes C6orf223 and microRNAs showed strong potential for accurate diagnosis. Methylation and mutation analyses revealed potential mechanisms enhancing C6orf223's stability and oncogenic activity. Our findings indicate that C6orf223 acts as a binder to and inhibits tumor-suppressive microRNAs, reducing their availability to regulate cancer-promoting genes and may serve as a valuable biomarker for CRC diagnosis and prognosis. Further research on lncRNA-microRNA interactions could provide insights for novel CRC therapies. - Source: PubMed
Publication date: 2025/09/16
Tutunchi SaraJavanmard Amir-RezaPanahi GhodratollahM Soltani BahramAkbari AtiehGhaderian Sayyed Mohammad Hossein - Protein arginine methyltransferase 5 (PRMT5) complexes with methylosome protein 50 (MEP50) play crucial roles in tumor progress. However, the regulatory mechanism of governing the PRMT5-MEP50 hetero-octameric complex remains unclear. Here, we demonstrate that C6orf223, to our knowledge an uncharacterized protein, facilitates PRMT5-MEP50 multiprotein complex assembling, thereby promoting colorectal cancer (CRC) growth and metastasis. C6orf223 forms dimers through disulfide bonds, with its N-terminal arginine-enriched region binding to the C-terminal negatively charged groove of PRMT5, thus stabilizing PRMT5-MEP50 multiprotein and enhancing PRMT5 methyltransferase activity. Consequently, PRMT5-mediated H4R3me2s substantially decreases the expression of the tumor suppressor GATA5, leading to the upregulation of multiple oncogenic target genes including WWTR1, FGFR1, and CLU. Targeting C6orf223 using siRNAs encapsulated in ferritin protein shells effectively suppresses CRC tumor growth and metastasis. Collectively, our findings characterize the role of C6orf223 in facilitating PRMT5-MEP50 hetero-octameric complex assembling and suggest that C6orf223 could serve as a potential therapeutic target for CRC. - Source: PubMed
Publication date: 2025/10/15
Qiao YufengWu ZhenzhenWang PengJin YiliangBai FurongZhang FeiAn YunheXue MeiyingFeng HanZhang YongHou YaxinDu JunfengCai HuiyunShi GuizhiZhou BingGao PuLou JizhongZhang PengFan KelongLiu JinboBu Pengcheng - This study investigates the molecular mechanisms of CC@AC&SF@PP NPs loaded with AC099850.3 siRNA and sorafenib (SF) for improving hepatitis B virus-related hepatocellular carcinoma (HBV-HCC). - Source: PubMed
Publication date: 2024/08/31
He AoxiaoHuang ZhihaoFeng QianZhang ShanLi FanLi DanLu HongchengWang Jiakun - Overall cancer hypomethylation had been identified in the past, but it is not clear exactly which hypomethylation site is the more important for the occurrence of cancer. To identify key hypomethylation sites, we studied the effect of hypomethylation in twelve regions on gene expression in colon adenocarcinoma (COAD). The key DNA methylation sites of cg18949415, cg22193385 and important genes of C6orf223, KRT7 were found by constructing a prognostic model, survival analysis and random combination prediction a series of in-depth systematic calculations and analyses, and the results were validated by GEO database, immune microenvironment, drug and functional enrichment analysis. Based on the expression values of C6orf223, KRT7 genes and the DNA methylation values of cg18949415, cg22193385 sites, the least diversity increment algorithm were used to predict COAD and normal sample. The 100 % reliability and 97.12 % correctness of predicting tumor samples were obtained in jackknife test. Moreover, we found that C6orf223 gene, cg18949415 site play a more important role than KRT7 gene, cg22193385 site in COAD. In addition, we investigate the impact of key methylation sites on three-dimensional chromatin structure. Our results will be help for experimental studies and may be an epigenetic biomarker for COAD. - Source: PubMed
Publication date: 2023/12/22
Bai HuiYan Dong-ShengChen Ying-LiLi Qian-ZhongQi Ye-Chen